Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Functions of voltage-gated potassium channels
3. Structure of voltage-gated channels
4. The superfamily of VGKCs ("Channome")
5. VGKCs directly implicated in cancer
6. Putative structure of the Kv10.1 monomer (1)
7. Kv10.1 expression is limited in peripheral tissue
8. Kv10.1 shows "oncogenic potential"
9. Immunohistochemistry using scFv anti Kv10.1
10. Kv10.1 in human tumor samples (IHC)
11. Kv10.1 expression is secondary
12. Mammary hyperplasia in MMTV-Kv10.1 mice (1)
13. Mammary hyperplasia in MMTV-Kv10.1 mice (2)
14. Increased malignancies in MMTV-Kv10.1 mice
15. Inhibition of Kv10.1 expression effect on tumors
16. Inhibition of Kv10.1 function effect on tumors
17. Permeation is not essential for tumorigenesis
18. Vascularization is increased by Kv10.1 expression
19. Kv10.1 expression in leukemias
20. Kv10.1 correlates with poor prognosis in AML
21. Cell lines and patient cells express Eag1
22. Kv10.1 inhibition impairs proliferation of leukemia
23. A need for a specific Kv10.1 blocker
24. Putative structure of the Kv10.1 monomer (2)
25. Immunogen design
26. mAb56 characterization: binding to intact cells
27. mAb56 characterization: specific binding
28. Inhibition of Kv10.1 by mAb56
29. mAb56 does not inhibit KV11.1 (HERG)
30. mAb56 inhibits tumor cell growth in vitro
31. mAb56 impairs proliferation of leukemia cells
32. mAb56 reduces tumor progression in vivo
33. Kv10.1 blockers and conventional chemotherapy
34. Kinetics of in vivo binding to tumor cells (mAb62)
35. Acknowledgements

Topics Covered

• Ion channels with relevant roles in oncology
• Kv10.1. Structure and expression profile
• Aberrant expression of KV10.1 in cancer cells
• Prognostic values of KV10.1 expression
• Therapeutic approaches using KV10.1 as target
• Functional antibodies against KV10.1 and their potential in oncology

Links

Series:

• Ion Channels

Categories:

• Biochemistry
• Cancer

Therapeutic Areas:

• Oncology

Talk Citation

Publication History

• Published on February 28, 2011

Financial Disclosures

• Prof. Luis Pardo, Stock Shareholder (Self-managed): iOnGen AG